great overviewhttps://promisneurosciences.com/wp-content/uploads/2021/07/ProMIS.final_.-OV.July-11-2021.pdf
This is a fantastic presentation.
I think they kept the COVID serology out to keep things streamlined and focused on the core competency of the company.
It is quite a pipeline. PMN310 alone is a good business plan for a company. But they have a capability. This tiny but talented company could become a major pharma player someday.